⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Yatrex Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Yatrex Pharmaceuticals
↗Luxembourg, Luxembourg
Yatrex Pharmaceuticals is a Luxembourg-based biopharmaceutical company focused on the development of preclinical therapeutic candidates for ischemia-related injuries in neurological and cardiovascular contexts. The company specializes in targeting acid-sensing ion channel 1 (ASIC1), which is a key mediator of tissue injury under ischemic and acidic conditions.
The company utilizes a multi-asset pipeline that combines proprietary tricyclic poly-arginine peptides with formulation-driven repurposing strategies. Their research is centered on strong biological and translational rationales, aiming to advance candidates toward IND-enabling development.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:CNS and Cardiovascular therapeutics
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:Peptides, Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LINKS
Website:yatrex.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Yatrex Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.